COMMUNIQUÉS West-GlobeNewswire

Virbac : Déclaration d'actions et de droits de vote 12/2024
10/01/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Ensuring the continuity of IBA's Entrepreneurial Anchoring
10/01/2025
Confirmation of the sale of IBA shares to Management Anchorage Louvain-la-Neuve, Belgium, 10 January 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, confirms that the sale by [...]
Pérennisation de l’ancrage entrepreneurial d’IBA
10/01/2025
Confirmation de la cession d’actions IBA à Management Anchorage Louvain-la-Neuve, Belgique, le 10 janvier 2025 - IBA (Ion Beam Applications SA), le leader mondial de la technologie des accélérateurs de particules, [...]
Adam Ferrari Health Science Scholarship Application Window Closes
10/01/2025
DENVER, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The application period for the 2024 Adam Ferrari Health Science Scholarship , sponsored by The Ferrari Foundation, has officially closed. This $20,000 scholarship program, [...]
Microbot Medical Closes $8.6 Million Registered Direct Offering
10/01/2025
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the [...]
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
10/01/2025
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, [...]
PETVIVO HOLDING, INC. ANNOUNCES PARTNERSHIP ENGAGEMENTS WITH VEDCO, INC. AND CLIPPER DISTRIBUTING, LLC
10/01/2025
MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) ("PetVivo"), a pioneering biomedical technology company focused on adapting human biotech, medical device and other [...]
Cytosurge annonce une transition stratégique de sa direction
10/01/2025
Simon Egli est nommé directeur général tandis que Pascal Behr, cofondateur, devient membre du conseil d’administration ZURICH, Suisse, 10 janv. 2025 (GLOBE NEWSWIRE) -- Cytosurge AG, leader de la manipulation [...]
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
10/01/2025
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase [...]
Les détecteurs Focus HD et le système de radiologie mobile DRX-Rise de Carestream reçoivent l’autorisation de marquage CE par l’Union européenne
10/01/2025
ROCHESTER, New York, 10 janv. 2025 (GLOBE NEWSWIRE) -- Carestream Health a annoncé ce jour avoir reçu l’autorisation de marquage CE de l’Union européenne pour ses détecteurs Focus HD et son système de radiologie mobile [...]
HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder
10/01/2025
Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related Depression MUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering [...]
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
10/01/2025
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and [...]
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
10/01/2025
In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA on confirmatory [...]
ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference
10/01/2025
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, [...]
Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD
10/01/2025
Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of [...]
OneMedNet Regains Compliance with NASDAQ Minimum Bid Price Requirements
10/01/2025
MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World [...]
Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot's Operations
10/01/2025
SCOTTSDALE, Ariz., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based functional beverage company, announced today new partnerships with [...]
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
10/01/2025
New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a [...]
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
10/01/2025
Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million [...]

Pages